Form 4: Incyte Director Bienaime Exercises Stock Options
Statement of Changes in Beneficial Ownership
Director Jean-Jacques Bienaime exercised 15,000 stock options and sold a portion to cover tax obligations.
Summary
- Director Jean-Jacques Bienaime exercised 15,000 non-qualified stock options at a strike price of $84.53 per share.
- The transaction was executed on May 26, 2026, pursuant to a Rule 10b5-1 trading plan.
- 13,059 shares were withheld by Incyte Corporation to satisfy tax withholding obligations at a market price of $97.10 per share.
- Following the transaction, the director holds 22,782 shares of Incyte common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative exercise of equity compensation by a director.
Positives
- The director maintains a significant equity stake of 22,782 shares in the company.
- The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating systematic rather than reactive trading.
Negatives
- The transaction resulted in a net reduction of shares held by the director after accounting for the tax-withholding sell-to-cover.
Risks
- Future share price volatility could impact the value of the director's remaining equity holdings.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine option exercises by directors under 10b5-1 plans are standard corporate governance practices in the biotechnology sector and generally do not signal a change in management sentiment regarding company prospects.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is a standard industry practice for executives to manage equity compensation while avoiding potential insider trading concerns.
- The sell-to-cover mechanism is a common method for executives to manage the tax liabilities associated with option exercises.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director granted power of attorney to company officers for SEC filing purposes. | 2026-05-05 | Administrative update to facilitate timely regulatory compliance. |
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned and represents standard compensation management.
Next Steps
- Future filings will be required if the director engages in further transactions involving company securities.
Key Dates
| Date | Description |
|---|---|
| 2026-05-05 | Date of Power of Attorney execution. |
| 2026-05-26 | Date of option exercise and share withholding transaction. |
| 2026-05-28 | Date of filing. |
Keywords
Incyte, INCY, Insider Trading, Stock Options, Form 4, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.